- CEO
- Ting Cun Wang
- Full Time Employees
- 1,256
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Guangzhou China
- IPO Date
- Apr 24, 2015
- Business
- Boji Medical Technology Co., Ltd. is a comprehensive contract research organization (CRO) and contract development and manufacturing organization (CDMO) that provides full-lifecycle, one-stop outsourcing services for the research, development, and production of pharmaceuticals, biopharmaceuticals, traditional Chinese medicines, and medical devices. The company operates through integrated business segments spanning drug discovery, preclinical testing, clinical trials, regulatory affairs, and commercial manufacturing. Its core service and product offerings include clinical research services, encompassing Phase I to IV clinical trial operations, bioequivalence (BE) studies, site management organization (SMO) services, medical writing, clinical data management, and biostatistical analysis; preclinical research services, comprising target screening, pharmacology, pharmacodynamics, pharmacokinetics, and Good Laboratory Practice (GLP)-compliant toxicology and safety evaluation; pharmaceutical development services, including active pharmaceutical ingredient (API) synthesis, formulation research, analytical method validation, and stability testing; contract development and manufacturing (CDMO/CMO) services, featuring pilot-scale development, chemical synthesis scale-up, finished dosage formulation production, and Marketing Authorization Holder (MAH) incubation; regulatory affairs consulting, delivering China National Medical Products Administration (NMPA) and U.S. Food and Drug Administration (FDA) dual-filing registration support, Investigational New Drug (IND) and New Drug Application (NDA) submissions, and pharmacovigilance; and medical device technical services, covering clinical trial management, performance testing, and product registration. Boji Medical serves multinational pharmaceutical enterprises, domestic drug developers, biotechnology companies, and academic research institutions across China and overseas international markets through subsidiaries such as BioTrialMed and Humphries Pharmaceutical Consulting in the United States. In recent developments, Boji Medical completed a private placement capital raise of approximately RMB 447.73 million to finance upgrades to its Drug Evaluation Center, expand its integrated CDMO/CRO capacities, accelerate proprietary and collaborative traditional Chinese medicine pipelines, and build an intelligent biomedical big data platform. The company also entered into a strategic collaboration with CapitalBio Pharma to advance traditional Chinese medicine R&D through integrated molecular herbal databases, established a strategic alliance with Zhejiang Maiyata Microbial Inspection Intelligent Technology to strengthen clinical operation frameworks and quality control for live biotherapeutic products (LBPs), and formed a joint venture to co-develop GBB101, an innovative long-acting injectable biologic targeted for chronic kidney disease-associated anemia. Founded in 2002, Boji Medical Technology Co., Ltd. is headquartered in Guangzhou, Guangdong Province, China.